Friday, December 8, 2023, 7:30 AM – 10:00 AM PT (10:30 AM – 1:00 PM ET)

Beyond the Guidelines: Clinical Investigator Perspectives on the Management of Follicular, Mantle Cell and Hodgkin Lymphoma (Part 1 of a 4-Part Series)

A CME Friday Satellite Symposium and Virtual Event Preceding the 65th ASH Annual Meeting

Location
Omni San Diego Hotel
675 L Street
San Diego, CA 92101
Phone: (619) 231-6664

Program Schedule — Pacific Time
7:00 AM – 7:30 AM — Registration and Breakfast
7:30 AM – 10:00 AM — Educational Meeting

Meeting Room
Grand Ballroom (Level 2)


This event will also be webcast live.
Please see Registration tab for details.
There is no registration fee for this event. For the in-person symposium in San Diego, preregistration is required as seating is limited.  
 
Faculty
Jeremy S Abramson, MD, MMSc
Director, Center for Lymphoma
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Stephen M Ansell, MD, PhD
Chair, Division of Hematology
Dorotha W and Grant L Sundquist Professor in
Hematologic Malignancies Research
Enterprise Deputy Director, Mayo Clinic Cancer Center
Mayo Clinic in Rochester, Minnesota
Rochester, Minnesota

Nancy L Bartlett, MD
Professor of Medicine
Koman Chair in Medical Oncology
Washington University School of Medicine
St Louis, Missouri


Jonathon B Cohen, MD
Associate Professor, Hematology and Medical Oncology
Co-Director, Lymphoma Program
Emory University Winship Cancer Institute
Atlanta, Georgia

Jonathan W Friedberg, MD, MMSc
Samuel E Durand Professor of Medicine
Director, James P Wilmot Cancer Institute
University of Rochester
Rochester, New York

Brad S Kahl, MD
Professor of Medicine
Washington University School of Medicine
Director, Lymphoma Program
Siteman Cancer Center
St Louis, Missouri

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, Genmab US Inc and AbbVie Inc, Merck, and Seagen Inc.
Program Schedule — Pacific Time
7:00 AM – 7:30 AM — Registration and Breakfast
7:30 AM – 10:00 AM — Educational Meeting

MODULE 1: Evolving Role of Novel Treatment Strategies for Follicular Lymphoma (FL) — Dr Friedberg

  • Appropriate integration of obinutuzumab into current FL treatment algorithms
  • Long-term clinical trial findings with lenalidomide/rituximab (R2) among patients with treatment-naïve and relapsed/refractory (R/R) FL; current role in clinical practice
  • Key findings with and optimal use of tazemetostat for R/R FL with and without EZH2 mutations
  • Rationale for combining tazemetostat with R2 for FL; early safety run-in data with and ongoing assessment of this combination among patients who have received 1 or more prior systemic therapies in the Phase Ib/III SYMPHONY-1 trial
  • Other promising therapies under investigation for newly diagnosed and R/R FL

MODULE 2: Integration of Chimeric Antigen Receptor (CAR) T-Cell Therapies and Bispecific Antibodies into the Management of FL — Dr Abramson

  • Principal outcomes with and selection of appropriate candidates for axicabtagene ciloleucel and tisagenlecleucel
  • Response rates and safety profile of lisocabtagene maraleucel in the Phase II TRANSCEND FL trial for patients with relapsed disease
  • Updated efficacy and safety data from the pivotal Phase II GO29781 study evaluating mosunetuzumab monotherapy for R/R FL
  • Recent FDA approval of mosunetuzumab; optimal incorporation opposite other available treatment options
  • Results from the Phase I/II EPCORE NHL-1 trial establishing the efficacy and safety of epcoritamab for R/R FL
  • Antitumor activity and toxicity documented with other bispecific antibodies (eg, glofitamab, odronextamab) alone and in combination with other systemic therapies
  • Incidence, severity and time course of cytokine release syndrome, neurotoxicity and other adverse events with bispecific antibodies and CAR T-cell therapy for FL

MODULE 3: Up-Front Treatment for Mantle Cell Lymphoma (MCL) — Dr Kahl

  • Factors affecting the selection of therapy for patients with newly diagnosed MCL
  • Available Phase III research findings with ibrutinib as a component of first-line treatment for MCL
  • Early outcomes with other Bruton tyrosine kinase (BTK) inhibitor-based combination regimens for previously untreated MCL; ongoing Phase III studies, such as ECHO, MANGROVE and ENRICH
  • Available data with and ongoing investigation of other novel agents as a component of first-line therapy

MODULE 4: Therapeutic Sequencing for Patients with R/R MCL — Dr Cohen

  • Long-term data supporting the FDA approvals of acalabrutinib and zanubrutinib for R/R MCL
  • Mechanisms of resistance to BTK inhibition; key findings among patients with R/R MCL from the Phase I/II BRUIN study of the noncovalent BTK inhibitor pirtobrutinib
  • Recent FDA approval of pirtobrutinib for R/R MCL; appropriate patient selection
  • FDA-approved indication for brexucabtagene autoleucel and optimal incorporation into current treatment algorithms
  • Recently presented results with lisocabtagene maraleucel for R/R MCL from the TRANSCEND NHL 001 trial
  • Ongoing investigation of other novel agents and strategies for MCL

MODULE 5: First-Line Treatment Strategies for Hodgkin Lymphoma (HL) — Dr Bartlett

  • Recent results from the Phase III SWOG S1826 study comparing nivolumab and doxorubicin/vinblastine/dacarbazine (AVD) to brentuximab vedotin (BV) and AVD for previously untreated advanced-stage classical Hodgkin lymphoma (cHL)
  • Overall survival and other key efficacy and safety outcomes from the Phase III ECHELON-1 trial evaluating BV and AVD versus ABVD for newly diagnosed advanced cHL
  • Available data with BV-based regimens for older patients with newly diagnosed advanced HL
  • Early findings with BV combined with chemotherapy and/or immunotherapy for early-stage, unfavorable-risk HL
  • Other studies exploring the utility of anti-PD-1/PD-L1 antibodies with chemotherapy for early- and advanced-stage HL

MODULE 6: Current and Future Management of R/R HL — Dr Ansell

  • Potential role of BV alone or with chemotherapy or immune checkpoint inhibition as a bridge to transplant
  • Key efficacy and safety findings from the Phase III KEYNOTE-204 trial evaluating pembrolizumab versus BV for R/R HL
  • Published data and ongoing evaluation of anti-PD-1/PD-L1 antibodies with other systemic approaches, such as BV or chemotherapy, for R/R HL
  • Principal efficacy and safety findings with and planned Phase III evaluation of camidanlumab tesirine for heavily pretreated HL
  • Other promising agents and strategies for patients with HL (eg, investigational immune checkpoint inhibitors, CAR T-cell therapy)

Target Audience
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of Hodgkin and non-Hodgkin lymphoma.

Learning Objectives
At the conclusion of this activity, participants should be able to

  • Understand published research data informing the selection, sequencing or combining of available therapeutic agents in the nonresearch care of patients with previously untreated or relapsed/refractory (R/R) follicular lymphoma (FL).
  • Evaluate the mechanisms of action of and available clinical trial findings with bispecific antibodies targeting CD20 x CD3 in patients with FL, and determine the role of these agents in current clinical management.
  • Consider patient age, performance status and other clinical and biological factors to optimize up-front and subsequent treatment of mantle cell lymphoma (MCL).
  • Review available research findings with Bruton tyrosine kinase (BTK) inhibitors as a component of induction therapy for MCL, and assess the risks and potential benefits of this strategy for patients who are eligible and not eligible for autologous stem cell transplant.
  • Discuss available clinical research findings demonstrating the efficacy and safety of noncovalent BTK inhibitors in patients with MCL, and use this information to evaluate the current role of these agents in therapy for R/R disease.
  • Assess available clinical trial findings informing the use of CD19-directed chimeric antigen receptor T-cell therapy for R/R FL and MCL, and counsel appropriately selected patients regarding the potential benefits of this strategy.
  • Incorporate available and emerging therapeutic strategies into the best-practice management of newly diagnosed and R/R Hodgkin lymphoma (HL).
  • Recall new data with agents and strategies currently under investigation for FL, MCL and HL, and consider the roles these may soon play, in addition to ongoing trial opportunities for eligible patients.

CME Credit Form
A CME credit link will be given to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — Dr Friedberg has no relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr Abramson — Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol Myers Squibb, Caribou Biosciences Inc, Cellectar Biosciences Inc, Century Therapeutics, Epizyme Inc, Genentech, a member of the Roche Group, Genmab US Inc, Incyte Corporation, Interius BioTherapeutics, Janssen Biotech Inc, Kite, A Gilead Company, Lilly, Regeneron Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc; Contracted Research: Bristol Myers Squibb, Cellectis, Merck, Mustang Bio, Seagen Inc. Dr Ansell — Contracted Research: ADC Therapeutics, Affimed, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Pfizer Inc, Regeneron Pharmaceuticals Inc, Seagen Inc, Takeda Pharmaceuticals USA Inc. Dr Bartlett — Advisory Committee: ADC Therapeutics, Foresight Diagnostics, Genentech, a member of the Roche Group, Kite, A Gilead Company; Contracted Research: ADC Therapeutics, Autolus Therapeutics, Bristol Myers Squibb, Celgene Corporation, Forty Seven Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc, Kite, A Gilead Company, Merck, Pharmacyclics LLC, an AbbVie Company, Seagen Inc, Takeda Pharmaceuticals USA Inc. Dr Cohen — Advisory Committee: AbbVie Inc, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, HUTCHMED, Janssen Biotech Inc, Kite, A Gilead Company, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company; Contracted Research: AI Therapeutics, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Celgene Corporation, Genentech, a member of the Roche Group, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Novartis, Takeda Pharmaceuticals USA Inc. Dr Friedberg — No relevant conflicts of interest to disclose. Dr Kahl — Consulting Agreements: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Celgene Corporation, Genentech, a member of the Roche Group, Genmab US Inc, Janssen Biotech Inc, Kite, A Gilead Company, Lilly, Novartis, Roche Laboratories Inc.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI Biopharma, a Sobi company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, Genmab US Inc and AbbVie Inc, Merck, and Seagen Inc.

Omni San Diego Hotel
675 L Street
San Diego, CA 92101
Phone: (619) 231-6664

Meeting Room
Grand Ballroom (Level 2)

Directions
Located directly across from the San Diego Convention Center, where the 2023 ASH Annual Meeting is taking place.

 
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of Hodgkin and non-Hodgkin lymphoma.

There is no fee to participate in this hybrid event. For the in-person symposium in San Diego preregistration is required as seating is limited.

NOTICE: Registration for this event is independent of registration for the ASH Annual Meeting.

IN-PERSON Registration

Thank you for your interest in our CME program. At this time online preregistration is closed for this event. SEATS ARE STILL AVAILABLE FOR THIS SESSION. Our Onsite Registration Desk will be open at 7:00 AM PT on Friday, December 8th. If you are interested in attending, please visit our registration desk located outside the Grand Ballroom (Level 2) of the Omni San Diego Hotel (675 L Street). Please note, onsite registration does not guarantee meal service.

Omni San Diego Hotel  is conveniently located 6 minutes (0.2 miles) from the San Diego Convention Center, where the 65th ASH Annual Meeting is taking place. ASH will be providing complimentary shuttle service between the convention center and participating conference hotels. Shuttle schedule information will be made available on the ASH conference website and also posted in the lobby of participating hotels. 

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com or call (800) 233-6153.

NOTICE: Registration for this event is independent of registration for the ASH Conference.

LIVE WEBCAST Registration for all professionals

Please note, we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

REGISTRATION FOR WEBCAST »
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.